ArmaGen aims to transform the treatment of severe neurological disorders by enabling transport of recombinant proteins, peptides and nucleic acids across the blood-brain barrier (BBB), addressing a clear unmet medical need in a majority of these diseases. We believe our therapeutic approach can make a real difference for patients and families living with these diseases.

Click here for an overview of ArmaGen’s research published in peer-reviewed publications.

ArmaGen’s chief executive officer, Mathias Schmidt, provides an overview on the company, its technology, and the potential of its broad pipeline

Engineering and developing revolutionary therapies for the brain.